Abstracts Archive - Page 1091 of 2425 - ACR Meeting Abstracts

Abstract Number: 1296 • 2018 ACR/ARHP Annual Meeting
A Novel Potent and Selective Urate Transporter 1 Inhibitor, NC-2700, with pH-Raising Effect on Low Urinary pH
Masuharu Hirano¹, Takafumi Muto¹, Toshitake Hirai², Promsuk Jutabha³, Naohiko Anzai⁴, Toru Horie⁵, Hitoshi Endou⁶ and Tomio Yamakawa⁷, ¹Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ²Nippon Chemiphar Co., Ltd., Misato, Saitama Prefecture, Japan, ³Dokkyo Medical University School of Medicine, Tochigi, Japan, ⁴Chiba University Graduate School of Medicine, Chiba, Japan, ⁵Dethree Res Lab Inc., Tsukuba, Japan, ⁶J-Pharma Co., Ltd., Yokohama, Japan, ⁷Discovery Research Laboratories, Nippon Chemiphar Co., Ltd., Misato, Saitama prefecture, Japan
Background/Purpose: In most patients with gout, renal underexcretion of uric acid is the main mechanism for hyperuricemia. However, for the risk of uric acid kidney…
Abstract Number: 1297 • 2018 ACR/ARHP Annual Meeting
Risk of Dementia in Patients with Gout and the Impact of Urate-Lowering Therapies: A Large Population-Based Cohort Study
Louise Crowley, Alyshah Abdul Sultan, Edward Roddy, Christian Mallen, Joanne Protheroe and Lorna Clarson, Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom
Background/Purpose: Evidence is conflicting concerning dementia risk in gout patients, with hyperuricaemia proposed to exert a neuroprotective effect. Serum urate (sUA) targets guiding urate-lowering therapies…
Abstract Number: 1298 • 2018 ACR/ARHP Annual Meeting
Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data
Jasvinder A. Singh and John Cleveland, Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: In the presence of limited available data, our objective was to assess the association of gout with the risk of incident Parkinson’s disease (PD)…
Abstract Number: 1299 • 2018 ACR/ARHP Annual Meeting
A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice
Danica Grujic¹, Aditi Desphande¹, Robert Terkeltaub², Nadia Mosiichuk³, Kateryna Goncharva⁴ and Stefan Pirzynowski⁴, ¹R&D, Allena Pharmaceuticals, Newton, MA, ²VA San Diego Healthcare System, San Diego, CA, ³SGPlus and Lund University, Lund, Sweden, ⁴Lund University and SGPlus, Lund, Sweden
A novel recombinant oral urate oxidase (UrOx) ALLN-346 reduces severe hyperuricemia and normalizes hyperuricosuria in nephropathic UrOx knockout (UrOxKO) miceBackground/Purpose: Limitations in efficacy and/or tolerance…
Abstract Number: 1300 • 2018 ACR/ARHP Annual Meeting
The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A Population Based Study
Mohamed Elsaid¹, Vinod Rustgi² and Naomi Schlesinger³, ¹Department of Epidemiology, Rutgers, The State University of New Jersey, New Brusnwick, NJ, ²Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ³Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: The metabolic syndrome (MS) is common among gout patients. The metabolic syndrome is diagnosed when a patient has at least 3 of the following…
Abstract Number: 1301 • 2018 ACR/ARHP Annual Meeting
Organic Anion Transport Inhibitors Suppress Chondrocyte Pyrophosphate Production
Mohammed Faseehuddin¹, Claudia Gohr², Elizabeth Mitton-Fitzgerald³ and Ann Rosenthal⁴, ¹Medicine/Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²Medicine, Medical College of Wisconsin, Milwaukee, WI, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁴Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from articular calcium pyrophosphate deposition leading to arthritis. We currently lack specific and effective therapies for this commonly…
Abstract Number: 1302 • 2018 ACR/ARHP Annual Meeting
Opioid Analgesic Use in Acute Gout Patients Discharged from the Hospital
Deepan Dalal¹, Nadine Mbuyi², Isha Shah³, Pieusha Malhotra⁴, Steven Reinert⁵ and Ross Hilliard⁶, ¹Rheumatology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ²Rheumatology, The Warren Alpert Medical School of Brown University, E. Providence, RI, ³Internal Medicine, The Warren Alpert Medical School of Brown University, Providence, RI, ⁴Rheumatology, Roger William Medical Center, Providence, RI, Providence, RI, ⁵Lifespan Information Services, Lifespan Information Services, Providence, RI, Providence, RI, ⁶Medicine, The Warren Alpert Medical School of Brown University, E. Providence, RI
Background/Purpose: The Health and Human Services has declared the opioid epidemic as a public health emergency. It has been demonstrated that even short exposures to…
Abstract Number: 1303 • 2018 ACR/ARHP Annual Meeting
Rituximab Versus Mycophenolate Mofetil in Interstitial Lung Disease Secondary to Connective Tissue Disease
Lisa Zhu¹, Shufeng Li², Laurence Gagne³, Susan Jacobs⁴, Julie Morisset³, Joshua Mooney⁵, Rishi Raj⁵ and Lorinda Chung⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Dermatology, Stanford University School of Medicine, Stanford, CA, ³Centre Hospitalier de l’Universite de Montreal, Montreal, QC, Canada, ⁴Stanford University, Palo Alto, CA, ⁵Pulmonary and Critical Care, Stanford University Medical Center, Palo Alto, CA, ⁶Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in connective tissue diseases (CTD). CTD-related ILD (CTD-ILD) has typically been treated…
Abstract Number: 1304 • 2018 ACR/ARHP Annual Meeting
Rituximab in Connective Tissue Disease – Associated Interstitial Lung Disease
Ana Catarina Duarte¹, Ana Cordeiro¹, Bruno Fernandes², Miguel Bernardes³, Catarina Tenazinha^4,5, Inês Cordeiro^4,5, Tnia Santiago^6,7, Maria Inês Seixas⁸, Ana Roxo Ribeiro⁹ and Maria José Santos^5,10, ¹Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ²Rheumatology Department, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ³Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ⁴Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Lisboa, Portugal, ⁵Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal, Lisboa, Portugal, ⁶Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, Coimbra, Portugal, ⁷Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Coimbra, Portugal, ⁸Rheumatology Unit, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, Viseu, Portugal, ⁹Rheumatology Unit, Hospital de S. Marcos, Braga, Portugal, Braga, Portugal, ¹⁰Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbi-mortality in patients (pts) with CTD. Small studies have recently demonstrated a promising role for…
Abstract Number: 1305 • 2018 ACR/ARHP Annual Meeting
Risk of Progression of Interstitial Lung Disease with Autoimmune Features to a Systemic Autoimmune Rheumatic Disease
Michail Alevizos and Elana J. Bernstein, Rheumatology, Columbia University, New York, NY
Background/Purpose: Approximately 15-25% of patients diagnosed with idiopathic interstitial lung disease (ILD) have some features of autoimmunity, yet do not meet classification criteria for a…
Abstract Number: 1306 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Patterns in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF)
Giorgos Loizidis¹, Nikhil Jiwrajka², Colin Ligon³, Mary Porteous² and Michael D. George⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Internal Medicine, Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) has recently been defined to describe patients with interstitial lung disease (ILD) with certain clinical, serologic, and/or morphologic…
Abstract Number: 1307 • 2018 ACR/ARHP Annual Meeting
Autoantibodies in Idiopathic Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features – a Prospective Study
Adelle S Jee^1,2, Jane F Bleasel^3,4, Stephen Adelstein^4,5,6, Lauren Troy^1,4, Helen Jo^1,4, Edmund Lau^1,4, Susanne Webster¹ and Tamera J Corte^7,8, ¹Respiratory and Sleep Department, Royal Prince Alfred Hospital, Sydney, Australia, ²Medicine Central clinical school, University of Sydney, Sydney, Australia, ³Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia, ⁴Faculty of Medicine, University of Sydney, Sydney, Australia, ⁵Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, Australia, ⁶Immunopathology Laboratory, South-west Sydney Pathology Service, Sydney, Australia, ⁷Royal Prince Alfred Hospital, Sydney, Australia, ⁸University of Sydney, Sydney, Australia
Background/Purpose: The detection of autoantibodies plays a vital role in the diagnosis of occult connective tissue disease (CTD) in patients with interstitial lung disease (ILD),…
Abstract Number: 1308 • 2018 ACR/ARHP Annual Meeting
Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD):a Single Center Study of 47 Patients
Madiha Tariq¹, Sunny Patel¹, Sarwat Umer², Gloria Caldito³ and Samina Hayat⁴, ¹Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, ²LSU Health Shreveport, Shreveport, LA, ³Neurology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, ⁴Rheumatology/Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA
Background/Purpose: Interstitial lung disease (ILD) is a fatal complication of connective tissue diseases (CTDs). Despite numerous advances in immunosuppressive agents, data on effective treatment for…
Abstract Number: 1309 • 2018 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features: Is It Frequent?
John Fredy Jaramillo Gallego¹, Marina Scolnik², Joaquin Maritano Furcada³, Maria Laura Acosta Felquer⁴, Nicolas Martin Marin Zucaro¹, Luciano Fernando Lo Giudice¹ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Pneumology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ⁴Rheumatology Unit, Internal Medicine Service,, Hospital Italiano de Buenos Aires, Capital Federal, Argentina
Background/Purpose: A particular subset of interstitial pneumonia, associated to one or more clinical and serological features, suggesting a possible underlying autoimmune disorder, has been described…
Abstract Number: 1310 • 2018 ACR/ARHP Annual Meeting
Diagnostic Utility of Myositis Antibodies in Patients with Interstitial Lung Disease and Suspected Underlying Connective Tissue Disease
Verónica Wolff¹, Juan Maya², Carolina Cuéllar³, Matías Florenzano¹, Alexis Peralta⁴ and Viviana Balboa⁴, ¹Rheumatic Lung diseases Unit, Instituto Nacional del Tórax, Santiago, Chile, ²Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, ³Rheumatology Section, Hospital del Salvador, Universidad de Chile, SANTIAGO, Chile, ⁴Laboratorio Inmunología, Hospital Del Salvador, SANTIAGO, Chile
Background/Purpose: Interstitial Lung Disease (ILD) is a common manifestation of Connective Tissue Diseases (CTD), mainly Systemic sclerosis (SSc), Rheumatoid Arthritis and Idiopathic Inflammatory Myositis (IIM)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].